Zentalis Pharmaceuticals (ZNTL) Payables (2019 - 2026)

Zentalis Pharmaceuticals' Payables history runs 8 years deep, the most recent figure standing at $7.4 million for Q1 2026.

• On a quarterly basis, Payables fell 5.03% year-over-year to $7.4 million in Q1 2026; TTM through Mar 2026 was $7.4 million, a 5.03% decrease from a year earlier, with the FY2025 full-year figure at $7.2 million, down 3.09% from the prior year.
• Payables rose to $7.4 million in Q1 2026 per ZNTL's latest filing, from $7.2 million in the prior quarter.
• Across five years, Payables topped out at $20.4 million in Q2 2024 and bottomed at $3.7 million in Q2 2025.
• The 5-year median for Payables is $10.5 million (2024), against an average of $10.6 million.
• Across the five-year window, Payables soared 66.11% in 2024 and sank 81.81% in 2025, its largest moves.
• Year by year, Payables stood at $11.2 million in 2022, then surged by 32.71% to $14.9 million in 2023, then sank by 50.17% to $7.4 million in 2024, then fell by 3.09% to $7.2 million in 2025, then grew by 2.36% to $7.4 million in 2026.
• Per Business Quant, the three latest ZNTL Payables figures stand at $7.4 million (Q1 2026), $7.2 million (Q4 2025), and $7.0 million (Q3 2025).